Valentina Tuninetti
Overview
Explore the profile of Valentina Tuninetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marandino L, Trastu F, Ghisoni E, Lombardi P, Mariniello A, Reale M, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000021.
PMID: 39886519
Objective: To assess time trends in the inclusion of health-related quality of life (QoL) among study endpoints and in the reporting of QoL results in study publications, randomised phase III...
2.
Tommasi O, Marchetti M, Tripepi M, Bigardi S, Incognito G, Tuninetti V, et al.
J Clin Med
. 2025 Jan;
14(2.
PMID: 39860407
Cancer immunotherapy through the use of PD-1/PD-L1 inhibitors have shown significant promise in endometrial carcinoma (EC), particularly in tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR), present in...
3.
Tuninetti V, Farolfi A, Rognone C, Montanari D, De Giorgi U, Valabrega G
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519001
The management of advanced endometrial cancer (EC) has changed in the last few years due to the introduction of a new molecular classification and the approval of immunotherapy. For a...
4.
Galvagno F, Leuci V, Massa A, Donini C, Rotolo R, Capellero S, et al.
Cancer Immunol Immunother
. 2024 Nov;
74(1):6.
PMID: 39487859
Intraperitoneal cellular immunotherapy with CAR-redirected lymphocytes is an intriguing approach to target peritoneal carcinomatosis (PC) from ovarian cancer (OC), which is currently evaluated in clinical trials. PC displays a composite...
5.
Spagnol G, Ghisoni E, Morotti M, Tommasi O, Marchetti M, Bigardi S, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000178
Immunotherapy, particularly the use of immune checkpoint inhibitors (ICIs), has shown limited efficacy in treating ovarian cancer (OC), possibly due to diverse T cell infiltration patterns in the tumor microenvironment....
6.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, et al.
Eur J Cancer
. 2024 Apr;
203:114039.
PMID: 38598922
Background: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with...
7.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, et al.
Front Oncol
. 2024 Feb;
13:1357793.
PMID: 38318323
[This corrects the article DOI: 10.3389/fonc.2023.1247291.].
8.
Turinetto M, Ricotti A, Marchetti C, Pisano C, Zamagni C, Cassani C, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201470
Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose...
9.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, et al.
Front Oncol
. 2023 Oct;
13:1247291.
PMID: 37781174
Introduction: Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%-15% of women with EC are diagnosed with...
10.
Tuninetti V, Pace L, Ghisoni E, Quara V, Arezzo F, Palicelli A, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509300
Background: There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status. Methodology: The RAME study is a retrospective analysis aiming...